Bionano Genomics, Inc. (BNGO) Stock

Bionano Genomics, Inc. (BNGO) is a Technology stock trading at $1.22 (as of 2026-08-20), with a market capitalization of $14.31M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Bionano Genomics provides genome analysis software and supporting products, including Saphyr for optical genome mapping–based structural variation analysis and NxClinical for interpreting genomic variants from microarray and next-generation sequencing data, along with related instruments, consumables, and computational resources. It also offers laboratory and testing services such as chromosomal microarray, Fragile X, exome sequencing, and EpiPanelDx, serving clinical and research users.

Understand Bionano Genomics, Inc.: how it makes money

Bionano Genomics provides genome analysis solutions, selling Saphyr (software plus a single-molecule imager instrument), Saphyr Chip consumables for DNA linearization, sample preparation and DNA labeling kits, and Saphyr and Bionano compute servers used for structural variation analysis via optical genome mapping.

The company’s profit model is tied to selling an end-to-end optical genome mapping workflow, combining the Saphyr analysis platform (software, instrument, and compute) with consumables (Saphyr Chip, Prep Kits, and DNA labeling kits).

Business quality (Weak): Good product clarity from the provided description, but no official reportable segment breakdown and no operating KPI labels were provided, limiting KPI-driven analysis.

Bull case

  • End-to-end workflow coverage: The company’s offerings span sample-to-result structural variation analysis, including Saphyr software, the Saphyr instrument, Saphyr Chip consumables, and Prep and labeling kits.
  • Platform depth: It also provides compute servers (Saphyr and Bionano compute), which supports analysis alongside the instrument and consumables.

Bear case

  • Loss-making at the operating level: The latest provided operating margin is negative (-118.1%), which indicates operating losses under the provided period.
  • Limited provided data for drivers: No operating KPI metrics or segment revenue breakdowns were provided, making it harder to pinpoint which part of the platform is driving results.
Valuation — source: SEC EDGAR (first-party)
Price$1.22
Market Cap$14.31M
Price / Book0.45
Price / Sales0.49
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$28.51M
Net Margin-92.6%
Revenue Growth (YoY)-7.4%
EPS Growth (YoY)-94.5%
Financial Health — source: SEC EDGAR
Altman Z-Score-14.16 (distress)
Valuation vs Sector & Industry
Sector P/E (Technology)33.9
Industry P/E (Measuring & Control Equipment)51.8
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderGSA CAPITAL PARTNERS LLP ($413000.00)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEORobert Erik Holmlin
Employees98
CountryUS
IPO Date2018-08-21

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Harvard Bioscience, Inc. (HBIO)
  • Quanterix Corporation (QTRX)
  • Nautilus Biotechnology, Inc. (NAUT)
  • Seer, Inc. (SEER)
  • Rapid Micro Biosystems, Inc. (RPID)
  • Precipio, Inc. (PRPO)
  • Birchtech Corp. (BCHT)
  • Astrotech Corporation (ASTC)
BNGO earnings history · BNGO institutional & insider holders · BNGO KPIs & operating metrics · BNGO financials · BNGO investor presentations & press releases · BNGO SEC filings · BNGO peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.